Developer docs
API playgroundTry for free, no card

Search company profiles

Seres Therapeutics

Full company profile

uuid0000u1w

Namestring
Seres Therapeutics
Legal namestring
Seres Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Seres Therapeutics is a clinical-stage biotechnology company developing a novel class of medicines based on rationally selected consortia of commensal bacteria (live biotherapeutics). Founded in 2012 as a Flagship Pioneering company and headquartered in Cambridge, Massachusetts, the company is publicly traded on NASDAQ under ticker MCRB. Its proprietary Live Biotherapeutics Engine integrates microbiome biomarker discovery, consortia design using a proprietary strain library, pharmacological validation, and cGMP manufacturing to produce oral bacterial consortia targeting serious diseases including bacterial bloodstream infections, antimicrobial resistant infections, and inflammatory bowel diseases.

The company's product portfolio consists of SER-155 (Phase 2-ready for preventing bloodstream infections in allogeneic hematopoietic stem cell transplant patients, with FDA Breakthrough Therapy and Fast Track designations), SER-603 (targeting ulcerative colitis, Crohn's disease, and immune checkpoint-related enterocolitis), and SER-147 (for chronic liver disease). Seres previously developed and obtained FDA approval for VOWST (fecal microbiota spores, live-brpk) in April 2023, the first-ever oral live biotherapeutic approved for prevention of recurrent C. difficile infection, but sold global rights to Nestlé Health Science in September 2024. The company has since reverted to a clinical-stage model without direct commercial operations.

Seres generates revenue primarily through milestone payments, non-dilutive grants (e.g., CARB-X funding of up to $3.6M for SER-155 liquid formulation development), and partnership arrangements. The 2026 amended agreement with Nestlé Health Science provides $25 million in two installments to buy out future VOWST milestones. Customer concentration is effectively a function of pipeline dependence on SER-155 and Nestlé as the sole commercial partner. The company serves medically vulnerable patient populations in hospital and specialty clinic settings, with future commercialization expected to be executed through partnership or licensing arrangements rather than direct sales.

Short descriptiontext

Seres Therapeutics is a clinical-stage biotechnology company developing orally-delivered live biotherapeutic products based on rationally selected bacterial consortia to prevent serious infections in medically vulnerable patients, including stem cell transplant recipients and those with inflammatory diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live biotherapeutics, microbiome therapeutics, bacterial consortia therapy, clinical-stage biotechnology, oral microbiome drugs
Industry3 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Microbiome Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1VOWST Product Sales (Discontinued)
TypeOne Time License
Description

Seres commercialized VOWST (fecal microbiota spores, live-brpk), the first FDA-approved oral live biotherapeutic for prevention of recurrent C. difficile infection, achieving commercial launch in 2023. The product rights were sold to Nestlé Health Science in September 2024 for future financial considerations including $25M in 2026 milestone buyout payments.

markets.financialcontent.com
2Non-Dilutive Funding (CARB-X)
TypeLicensing Royalties
Description

Seres received up to $3.6 million in non-dilutive funding from CARB-X to support development of an oral liquid formulation of SER-155 for preventing bloodstream infections in vulnerable patient populations.

globenewswire.com
3Partnership Payments
TypeLicensing Royalties
Description

Nestlé Health Science provides $25 million in cash payments during 2026 under an amended agreement, buying out potential future VOWST net sales milestone payments, providing near-term capital certainty.

citybiz.co
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Seres Therapeutics develops oral live biotherapeutic products composed of rationally selected consortia of commensal bacteria, designed to prevent bacterial bloodstream and antimicrobial-resistant infections in medically vulnerable patients and to treat GI-related immune diseases. The company's lead clinical asset SER-155 targets allogeneic hematopoietic stem cell transplant patients, while pipeline candidates SER-603 and SER-147 address inflammatory bowel disease and chronic liver disease, respectively. All candidates are built on Seres' proprietary Live Biotherapeutics Engine, an integrated platform for microbiome biomarker discovery, consortia design, pharmacological validation, and cGMP manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 88% response rate in preventing infection recurrence at up to eight weeks (VOWST clinical studies)
+2 more records
Product overview1 text field

Seres Therapeutics is a clinical-stage biotechnology company that has developed an entirely new class of potential medicines based on rationally selected live bacterial consortia. The company's portfolio consists of VOWST (fecal microbiota spores, live-brpk), the first-ever FDA-approved oral live biotherapeutic (commercial rights sold to Nestlé Health Science in September 2024), and a pipeline of investigational live biotherapeutics including SER-155 (Phase 2-ready for preventing bloodstream infections in allo-HSCT patients), SER-603 (for ulcerative colitis, Crohn's disease, and immune checkpoint related enterocolitis), and SER-147 (for chronic liver disease). All products are built on Seres' Live Biotherapeutics Engine platform, which combines microbiome biomarker discovery, consortia design, pharmacological validation, and advanced manufacturing to create multifunctional bacterial consortia delivered as oral formulations.

Product and service4 records
1VOWST (fecal microbiota spores, live-brpk)
CategoryCommercial product (discontinued/divested)
Description

Oral live biotherapeutic for prevention of recurrent Clostridioides difficile infection in adults; originally commercialized by Seres, with rights sold to Nestlé Health Science in September 2024.

2SER-155
CategoryPipeline product (Phase 2-ready)
Description

Investigational oral live biotherapeutic designed to decolonize gastrointestinal pathogens, improve epithelial barrier integrity, and induce immune tolerance to prevent bacterial bloodstream and antimicrobial-resistant infections in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients; Phase 1b showed significant reduction in bloodstream infections and systemic antibiotic exposure through day 100 post allo-HSCT.

3SER-603
CategoryPipeline product
Description

Investigational live biotherapeutic targeting inflammatory and immune diseases including ulcerative colitis, Crohn's disease, and immune checkpoint inhibitor-related enterocolitis.

4SER-147
CategoryPipeline product
Description

Investigational live biotherapeutic in development for chronic liver disease, designed to modulate the gastrointestinal microbiome to address infection-related complications in this patient population.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Nestlé Health Science acquired global rights to VOWST from Seres Therapeutics in September 2024. In 2026, Nestlé provided $25 million in two installments (July and October 2026) to buy out potential future VOWST net sales milestone payments. Nestlé joined the Microbiome Therapeutics Innovation Group (MTIG) and is collaborating with Seres to advance microbiome-based products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic research collaboration aimed at defining microbiome signatures of disease in high-risk patient populations and enabling streamlined access to patients. Memorial Sloan Kettering is conducting an investigator-sponsored trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership focused on inflammatory bowel disease (IBD) research. CCF is a non-profit organization dedicated to finding cures for Crohn's disease and ulcerative colitis and improving quality of life for those affected.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Directly comparable to Seres' rationally selected consortia platform approach, with overlapping indications in IBD and infectious disease.

TypeDirect peer
Description

European clinical-stage microbiome therapeutics company developing standardized, full-spectrum microbiome therapies. Direct comparable to SER-155 as MaaT Pharma's lead program targets improving survival in allo-HSCT patients with GvHD — the same patient population as SER-155.

TypeDirect peer
Description

Developer of Rebyota, the first FDA-approved microbiome-based therapy for prevention of recurrent C. difficile infection — the same indication Seres' VOWST originally addressed. Direct competitor in the microbiome therapeutics space, now part of Ferring's broader specialty GI portfolio.

TypeEmerging player
Description

Clinical-stage biotechnology company developing microbiome-targeted therapies for inflammatory diseases, including ulcerative colitis — directly overlapping with Seres' SER-603 program. Comparable as a small-cap microbiome player with GI/inflammatory disease focus.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing single-strain microbial medicines for inflammatory diseases. Direct peer in the broader microbiome therapeutics category, though facing its own pipeline and capital challenges that make it a cautionary comparable.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies, particularly in immuno-oncology and inflammatory diseases. Comparable as a peer in using microbiome science to develop novel therapeutics with similar platform-based approaches.

TypeDirect peer
Description

Was a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota therapies, including for recurrent C. difficile. Direct historical peer in microbiome therapeutics, though restructured; provides cautionary comparison on capital-intensive clinical execution.

8Second Genome
TypeEmerging player
Description

Clinical-stage biotechnology company using microbiome science for drug discovery and development, including in immuno-oncology and inflammatory diseases. Comparable as a peer in platform-based microbiome therapeutic development.

TypeBroad incumbent
Description

Specialty pharmaceutical company with established microbiome franchise (Rebyota). Relevant as a broader incumbent that acquired Rebiotix to compete in the C. diff microbiome space and represents the type of strategic acquirer/partner relevant to Seres' pipeline.

TypeBroad incumbent
Description

Global pharmaceutical company with significant GI and specialty therapeutics franchise. Relevant as a broad incumbent with the commercial scale and indication overlap (transplant, IBD, GI) to potentially partner with or acquire Seres assets, and an indirect competitor for hospital-administered specialty therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seres Therapeutics

Microbiome Therapeuticsserestherapeutics.com

Seres Therapeutics is a clinical-stage biotechnology company developing orally-delivered live biotherapeutic products based on rationally selected bacterial consortia to prevent serious infections in medically vulnerable patients, including stem cell transplant recipients and those with inflammatory diseases.

What Seres Therapeutics does

Seres Therapeutics is a clinical-stage biotechnology company developing a novel class of medicines based on rationally selected consortia of commensal bacteria (live biotherapeutics). Founded in 2012 as a Flagship Pioneering company and headquartered in Cambridge, Massachusetts, the company is publicly traded on NASDAQ under ticker MCRB. Its proprietary Live Biotherapeutics Engine integrates microbiome biomarker discovery, consortia design using a proprietary strain library, pharmacological validation, and cGMP manufacturing to produce oral bacterial consortia targeting serious diseases including bacterial bloodstream infections, antimicrobial resistant infections, and inflammatory bowel diseases.

The company's product portfolio consists of SER-155 (Phase 2-ready for preventing bloodstream infections in allogeneic hematopoietic stem cell transplant patients, with FDA Breakthrough Therapy and Fast Track designations), SER-603 (targeting ulcerative colitis, Crohn's disease, and immune checkpoint-related enterocolitis), and SER-147 (for chronic liver disease). Seres previously developed and obtained FDA approval for VOWST (fecal microbiota spores, live-brpk) in April 2023, the first-ever oral live biotherapeutic approved for prevention of recurrent C. difficile infection, but sold global rights to Nestlé Health Science in September 2024. The company has since reverted to a clinical-stage model without direct commercial operations.

Seres generates revenue primarily through milestone payments, non-dilutive grants (e.g., CARB-X funding of up to $3.6M for SER-155 liquid formulation development), and partnership arrangements. The 2026 amended agreement with Nestlé Health Science provides $25 million in two installments to buy out future VOWST milestones. Customer concentration is effectively a function of pipeline dependence on SER-155 and Nestlé as the sole commercial partner. The company serves medically vulnerable patient populations in hospital and specialty clinic settings, with future commercialization expected to be executed through partnership or licensing arrangements rather than direct sales.

Seres Therapeutics firmographics

Firmographics
Name
Seres Therapeutics
Legal name
Seres Therapeutics, Inc.
Website
https://serestherapeutics.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Seres Therapeutics is a clinical-stage biotechnology company developing orally-delivered live biotherapeutic products based on rationally selected bacterial consortia to prevent serious infections in medically vulnerable patients, including stem cell transplant recipients and those with inflammatory diseases.
Ownership category
akta.pro rank

Seres Therapeutics industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals

Keywords

  • Live biotherapeutics
  • Microbiome therapeutics
  • Bacterial consortia therapy
  • Clinical-stage biotechnology
  • Oral microbiome drugs

Where Seres Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Seres Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. VOWST Product Sales (Discontinued): Seres commercialized VOWST (fecal microbiota spores, live-brpk), the first FDA-approved oral live biotherapeutic for prevention of recurrent C. difficile infection, achieving commercial launch in 2023. The product rights were sold to Nestlé Health Science in September 2024 for future financial considerations including $25M in 2026 milestone buyout payments.
  2. Non-Dilutive Funding (CARB-X): Seres received up to $3.6 million in non-dilutive funding from CARB-X to support development of an oral liquid formulation of SER-155 for preventing bloodstream infections in vulnerable patient populations.
  3. Partnership Payments: Nestlé Health Science provides $25 million in cash payments during 2026 under an amended agreement, buying out potential future VOWST net sales milestone payments, providing near-term capital certainty.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Seres Therapeutics product offering

Product offering

Core offering

Seres Therapeutics develops oral live biotherapeutic products composed of rationally selected consortia of commensal bacteria, designed to prevent bacterial bloodstream and antimicrobial-resistant infections in medically vulnerable patients and to treat GI-related immune diseases. The company's lead clinical asset SER-155 targets allogeneic hematopoietic stem cell transplant patients, while pipeline candidates SER-603 and SER-147 address inflammatory bowel disease and chronic liver disease, respectively. All candidates are built on Seres' proprietary Live Biotherapeutics Engine, an integrated platform for microbiome biomarker discovery, consortia design, pharmacological validation, and cGMP manufacturing.

Product overview

Seres Therapeutics is a clinical-stage biotechnology company that has developed an entirely new class of potential medicines based on rationally selected live bacterial consortia. The company's portfolio consists of VOWST (fecal microbiota spores, live-brpk), the first-ever FDA-approved oral live biotherapeutic (commercial rights sold to Nestlé Health Science in September 2024), and a pipeline of investigational live biotherapeutics including SER-155 (Phase 2-ready for preventing bloodstream infections in allo-HSCT patients), SER-603 (for ulcerative colitis, Crohn's disease, and immune checkpoint related enterocolitis), and SER-147 (for chronic liver disease). All products are built on Seres' Live Biotherapeutics Engine platform, which combines microbiome biomarker discovery, consortia design, pharmacological validation, and advanced manufacturing to create multifunctional bacterial consortia delivered as oral formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • VOWST (fecal microbiota spores, live-brpk) Oral live biotherapeutic for prevention of recurrent Clostridioides difficile infection in adults; originally commercialized by Seres, with rights sold to Nestlé Health Science in September 2024.
  • SER-155 Investigational oral live biotherapeutic designed to decolonize gastrointestinal pathogens, improve epithelial barrier integrity, and induce immune tolerance to prevent bacterial bloodstream and antimicrobial-resistant infections in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients; Phase 1b showed significant reduction in bloodstream infections and systemic antibiotic exposure through day 100 post allo-HSCT.
  • SER-603 Investigational live biotherapeutic targeting inflammatory and immune diseases including ulcerative colitis, Crohn's disease, and immune checkpoint inhibitor-related enterocolitis.
  • SER-147 Investigational live biotherapeutic in development for chronic liver disease, designed to modulate the gastrointestinal microbiome to address infection-related complications in this patient population.

Quantifiable outcome

  • 88% response rate in preventing infection recurrence at up to eight weeks (VOWST clinical studies)
  • +2 more outcomes

Companies that use Seres Therapeutics

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Seres Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Seres Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Nestlé Health SciencecoreStrategic or Co-development Partner · 30 September 2024Nestlé Health Science acquired global rights to VOWST from Seres Therapeutics in September 2024. In 2026, Nestlé provided $25 million in two installments (July and October 2026) to buy out potential future VOWST net sales milestone payments. Nestlé joined the Microbiome Therapeutics Innovation Group (MTIG) and is collaborating with Seres to advance microbiome-based products.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerStrategic research collaboration aimed at defining microbiome signatures of disease in high-risk patient populations and enabling streamlined access to patients. Memorial Sloan Kettering is conducting an investigator-sponsored trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis.
  • Crohn's & Colitis Foundation (CCF)minorStrategic or Co-development PartnerPartnership focused on inflammatory bowel disease (IBD) research. CCF is a non-profit organization dedicated to finding cures for Crohn's disease and ulcerative colitis and improving quality of life for those affected.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Seres Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Directly comparable to Seres' rationally selected consortia platform approach, with overlapping indications in IBD and infectious disease.
  • MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardized, full-spectrum microbiome therapies. Direct comparable to SER-155 as MaaT Pharma's lead program targets improving survival in allo-HSCT patients with GvHD — the same patient population as SER-155.
  • Rebiotix (Ferring Pharmaceuticals): Developer of Rebyota, the first FDA-approved microbiome-based therapy for prevention of recurrent C. difficile infection — the same indication Seres' VOWST originally addressed. Direct competitor in the microbiome therapeutics space, now part of Ferring's broader specialty GI portfolio.
  • Evelo Biosciences: Clinical-stage microbiome therapeutics company developing single-strain microbial medicines for inflammatory diseases. Direct peer in the broader microbiome therapeutics category, though facing its own pipeline and capital challenges that make it a cautionary comparable.
  • Enterome: Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies, particularly in immuno-oncology and inflammatory diseases. Comparable as a peer in using microbiome science to develop novel therapeutics with similar platform-based approaches.
  • Finch Therapeutics: Was a clinical-stage microbiome therapeutics company developing Full-Spectrum Microbiota therapies, including for recurrent C. difficile. Direct historical peer in microbiome therapeutics, though restructured; provides cautionary comparison on capital-intensive clinical execution.

Emerging players

  • Assembly Biosciences: Clinical-stage biotechnology company developing microbiome-targeted therapies for inflammatory diseases, including ulcerative colitis — directly overlapping with Seres' SER-603 program. Comparable as a small-cap microbiome player with GI/inflammatory disease focus.
  • Second Genome: Clinical-stage biotechnology company using microbiome science for drug discovery and development, including in immuno-oncology and inflammatory diseases. Comparable as a peer in platform-based microbiome therapeutic development.

Broad incumbents

  • Ferring Pharmaceuticals: Specialty pharmaceutical company with established microbiome franchise (Rebyota). Relevant as a broader incumbent that acquired Rebiotix to compete in the C. diff microbiome space and represents the type of strategic acquirer/partner relevant to Seres' pipeline.
  • Takeda Pharmaceutical: Global pharmaceutical company with significant GI and specialty therapeutics franchise. Relevant as a broad incumbent with the commercial scale and indication overlap (transplant, IBD, GI) to potentially partner with or acquire Seres assets, and an indirect competitor for hospital-administered specialty therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Seres Therapeutics social profiles

Digital presence

Seres Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seres Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Seres Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seres Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seres Therapeutics

What does Seres Therapeutics do?

Seres Therapeutics develops oral live biotherapeutic products composed of rationally selected consortia of commensal bacteria, designed to prevent bacterial bloodstream and antimicrobial-resistant infections in medically vulnerable patients and to treat GI-related immune diseases. The company's lead clinical asset SER-155 targets allogeneic hematopoietic stem cell transplant patients, while pipeline candidates SER-603 and SER-147 address inflammatory bowel disease and chronic liver disease, respectively. All candidates are built on Seres' proprietary Live Biotherapeutics Engine, an integrated platform for microbiome biomarker discovery, consortia design, pharmacological validation, and cGMP manufacturing.

Is Seres Therapeutics a public or private company?

Seres Therapeutics is a public company. It is classified as public and is currently operating.

When was Seres Therapeutics founded?

Seres Therapeutics was founded in 2012. It employs 101 to 250 people.

Where is Seres Therapeutics based?

Seres Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Seres Therapeutics make money?

Three revenue lines are on record. VOWST Product Sales (Discontinued) is the primary driver. The others are non-Dilutive Funding (CARB-X) and partnership Payments.

Who are Seres Therapeutics's main competitors?

Direct peers on record are Vedanta Biosciences, MaaT Pharma, Rebiotix (Ferring Pharmaceuticals), Evelo Biosciences, Enterome and Finch Therapeutics. Emerging players are Assembly Biosciences and Second Genome. Broad incumbents are Ferring Pharmaceuticals and Takeda Pharmaceutical.

Does Seres Therapeutics have an API?

No public API is recorded for Seres Therapeutics.

What industry is Seres Therapeutics in?

Seres Therapeutics's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerSeres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Seres Therapeutics reported Q3 2026 revenue of $0.593 million and a net loss of $16.29 million, compared to $0.351 million revenue and $8.2 million net income a year ago. Nine-month revenue was $1.69 million versus $0.351 million, with a net loss of $31.62 million versus $21.03 million income. The company is developing SER-155 for allo-HSCT patients.Investing.comSeres reports 77% reduction in bloodstream infections in trialSeres Therapeutics published Phase 1b trial results for SER-155, an oral live biotherapeutic, in Nature Medicine. The trial showed bloodstream infections in 10% of SER-155 patients versus 42.9% on placebo, a 77% relative risk reduction. The drug has FDA Breakthrough and Fast Track designations, and is Phase 2-ready pending funding.Business & FinancialSeres Therapeutics Announces Publication Of SER-155 Phase 1B Results In Nature Medicine Showing Reduced Bloodstream Infections In Allogeneic Hematopoietic Cell Transplantation RecipientsSeres Therapeutics published Phase 1b trial results for SER-155 in Nature Medicine, showing a 77% relative risk reduction in bloodstream infections in allogeneic hematopoietic cell transplant recipients. The oral live biotherapeutic was well tolerated, with lower antibiotic exposure and improved gut barrier biomarkers. The company is Phase 2-ready pending funding.The future of tradingSeres Therapeutics, Inc. <mcrb.oq> expected to post a loss of 100 cents a share - Earnings PreviewSeres Therapeutics is expected to report a 1,709.1% revenue increase to $6.35 million for the quarter ending September 30, 2026, with a loss of 100 cents per share. Analysts rate the stock a buy, and the median 12-month price target is $17.00, about 771.8% above the last closing price.The future of tradingSeres Therapeutics CFO Marella Thorell Resigns, Effective November 15, 2026Seres Therapeutics CFO Marella Thorell resigned on Oct. 22, 2026, effective Nov. 15, 2026. She will provide advisory services to support an orderly transition. The resignation was filed via EDGAR on Oct. 26, 2026.Stock TitanSeres Therapeutics to present SER-428 data at IDWeekSeres Therapeutics will present preclinical data for SER-428, an oral liquid live biotherapeutic, at IDWeek 2026. The data show up to a 1,000-fold reduction of Enterococcus faecium and Klebsiella pneumoniae in preclinical models. The company is designing a Phase 1b trial for ICU patients, pending funding.Markets DailyContrasting Aligos Therapeutics (NASDAQ:ALGS) and Seres Therapeutics (NASDAQ:MCRB)Aligos Therapeutics and Seres Therapeutics are compared on ratings, valuation, and risk. Aligos has a stronger consensus rating and higher upside, while Seres trades at a lower price-to-earnings ratio. Aligos beats Seres on 10 of 15 factors.American Banking and Market NewsFinancial Analysis: Celldex Therapeutics (NASDAQ:CLDX) and Seres Therapeutics (NASDAQ:MCRB)Seres Therapeutics and Celldex Therapeutics are compared on valuation, earnings, analyst ratings, and risk. Seres has higher revenue and earnings, but Celldex trades at a lower P/E ratio. Analysts favor Seres with a higher upside target.Markets DailyContrasting Celldex Therapeutics (NASDAQ:CLDX) & Seres Therapeutics (NASDAQ:MCRB)Celldex Therapeutics and Seres Therapeutics are compared on valuation, analyst ratings, and institutional ownership. Seres has higher earnings and a higher upside potential, while Celldex trades at a lower price-to-earnings ratio. Analysts favor Seres, citing a 239% upside versus Celldex's 53%.Ticker ReportComparing Seres Therapeutics (NASDAQ:MCRB) and Aligos Therapeutics (NASDAQ:ALGS)Aligos Therapeutics and Seres Therapeutics are compared on valuation, risk, and analyst ratings. Aligos has higher revenue and a stronger consensus rating with a 637.55% upside, while Seres trades at a lower P/E but has lower revenue. Analysts favor Aligos based on these metrics.